Seegene has introduced a syndromic PCR-based test for simultaneous detection of STIs and HPV. Company data show co-detection in 71% of positive cases, supporting potential clinical utility for comprehensive reproductive infection screening.
QIAGEN’s FDA-cleared QIAstat-Dx panel detects Cyclospora cayetanensis, addressing a surge of over 1,600 confirmed US cases since May 2026.
A randomized trial found Cepheid’s Xpert Xpress MVP test improved appropriate treatment rates for vaginitis within 24 hours compared to standard diagnostic methods.
Emerging Andes virus cases—capable of person-to-person transmission—are prompting US clinical labs to reassess hantavirus protocols and consider travel and epidemiologic exposures beyond rodent contact.
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
Diasorin has received FDA 510(k) clearance for its customizable LIAISON PLEX Gastrointestinal Flex Assay, allowing labs to select from 24 targets to tailor testing based on patient needs and operational priorities.
Research identifies how circulating tumor DNA can inform personalized treatment and surveillance strategies.